107 related articles for article (PubMed ID: 25667473)
1. Neoadjuvant docetaxel/cyclophosphamide in triple-negative breast cancer: predictive value of class III-β tubulin and non-basal subtype.
Shimada K; Ishikawa T; Kita K; Narui K; Sugae S; Shimizu D; Tanabe M; Sasaki T; Chishima T; Ichikawa Y; Endo I
Anticancer Res; 2015 Feb; 35(2):907-12. PubMed ID: 25667473
[TBL] [Abstract][Full Text] [Related]
2. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer.
Nakatsukasa K; Koyama H; Oouchi Y; Imanishi S; Mizuta N; Sakaguchi K; Fujita Y; Fujiwara I; Kotani T; Matsuda T; Fukuda K; Morita M; Kawakami S; Kadotani Y; Konishi E; Yanagisawa A; Taguchi T
Breast Cancer; 2017 Jan; 24(1):63-68. PubMed ID: 26754092
[TBL] [Abstract][Full Text] [Related]
5. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
[TBL] [Abstract][Full Text] [Related]
6. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
[TBL] [Abstract][Full Text] [Related]
7. Basal-like molecular subtype and HER4 up-regulation and response to neoadjuvant chemotherapy in breast cancer.
Stickeler E; Pils D; Klar M; Orlowsk-Volk M; Zur Hausen A; Jäger M; Watermann D; Gitsch G; Zeillinger R; Tempfer CB
Oncol Rep; 2011 Oct; 26(4):1037-45. PubMed ID: 21769435
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(2):366-71. PubMed ID: 23818347
[TBL] [Abstract][Full Text] [Related]
9. BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy.
Dumontet C; Krajewska M; Treilleux I; Mackey JR; Martin M; Rupin M; Lafanechère L; Reed JC
Clin Cancer Res; 2010 Aug; 16(15):3988-97. PubMed ID: 20576719
[TBL] [Abstract][Full Text] [Related]
10. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
Kariya S; Ogawa Y; Nishioka A; Moriki T; Ohnishi T; Ito S; Murata Y; Yoshida S
Radiat Med; 2005 May; 23(3):189-94. PubMed ID: 15940066
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
[TBL] [Abstract][Full Text] [Related]
12. Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.
Nabholtz JM; Chalabi N; Radosevic-Robin N; Dauplat MM; Mouret-Reynier MA; Van Praagh I; Servent V; Jacquin JP; Benmammar KE; Kullab S; Bahadoor MR; Kwiatkowski F; Cayre A; Abrial C; Durando X; Bignon YJ; Chollet P; Penault-Llorca F
Int J Cancer; 2016 May; 138(9):2274-80. PubMed ID: 26649807
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
14. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
15. BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane.
Ishikawa T; Narui K; Tanabe M; Kida K; Oba MS; Yamada A; Ichikawa Y; Endo I
Eur J Surg Oncol; 2016 Jul; 42(7):999-1001. PubMed ID: 27041672
[TBL] [Abstract][Full Text] [Related]
16. [Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients].
Liu L; Li XR; Hu YH; Zhang J
Zhonghua Yi Xue Za Zhi; 2016 Mar; 96(12):940-3. PubMed ID: 27045718
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.
Masuda N; Higaki K; Takano T; Matsunami N; Morimoto T; Ohtani S; Mizutani M; Miyamoto T; Kuroi K; Ohno S; Morita S; Toi M
Cancer Chemother Pharmacol; 2014 Aug; 74(2):229-38. PubMed ID: 24871032
[TBL] [Abstract][Full Text] [Related]
18. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.
Zhou B; Yang DQ; Xie F
Chin Med J (Engl); 2008 Mar; 121(5):387-91. PubMed ID: 18364105
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
20. Impact of tumor biology, particularly triple-negative status, on response to pre-operative sequential, dose-dense epirubicin, cyclophosphamide followed by docetaxel in breast cancer.
Warm M; Kates R; Grosse-Onnebrink E; Stoff-Khalili M; Hoopmann M; Mallmann P; Thomas A; Harbeck N
Anticancer Res; 2010 Oct; 30(10):4251-9. PubMed ID: 21036749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
